It is well established that β-catenin/TCF signalling plays a role in cancer cell proliferation [14], and consequently targeting this pathway has been previously utilized to suppress tumour growth [7,15,16], but this approach has not previously been applied to a cardiovascular disease model. Here, HNF4A is linked to cardiovascular disorder.